Prostate Cancer
Feature
New trials in prostate cancer: Could your patient benefit?
Several new trials have opened in recent months.
From the Journals
Risky drinking common in cancer survivors
The numbers are “staggering. Most concerning ... is that those on cancer treatment are engaged in a similar level of risky drinking.”
News from the FDA/CDC
FDA OKs combo therapy of niraparib, abiraterone acetate for prostate cancer
This new agent "brings an important treatment option to patients with prostate cancer as they consider their road ahead."
From the Journals
MRI-guided SBRT cuts radiation toxicity in prostate cancer
“These findings suggest that the technical advantages in precision of radiotherapy delivery afforded by MRI-guided SBRT translate to measurable...
Conference Coverage
‘Treatment holiday’ in prostate cancer with tailored dosing
“Personalizing dosing intervals using early-response biomarkers with 177Lu-PSMA has the potential to achieve similar overall treatment...
From the Journals
Risk of falls seen with newer antiandrogens for prostate cancer
The take-home message is that the findings give men – and the physicians who counsel them – a fuller idea of what to expect when considering using...
Commentary
COVID can mimic prostate cancer symptoms
“I had none of those previously reported experiences that could suddenly trigger a spike in PSA.”
Conference Coverage
Plant-based diet linked to better outcomes in prostate cancer
Men who consumed more fruits and vegetables had slower cancer progression and lower risk of recurrence.
Conference Coverage
Prostate cancer subgroup may benefit from intensified therapy
A new trial explored whether for patients with prostate cancer who have unfavorable features and a detectable PSA following a radical...
Conference Coverage
Talazoparib add-on improves outcomes in metastatic prostate cancer
As determined on the basis of imaging, PFS was 37% better for talazoparib plus enzalutamide than for enzalutamide monotherapy.
Conference Coverage
Rucaparib benefit in BRCA+ prostate cancer confirmed
New study finding provides evidence of clinical benefit for an indication for rucaparib that was granted an accelerated approval in May 2020.